Know Cancer

or
forgot password

CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors


Phase 3
N/A
N/A
Open (Enrolling)
Both
Brain Cancer, Choroid Plexus Tumors

Thank you

Trial Information

CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors


Tissue Banking:

If you agree, samples of your leftover tissue (left over from standard care procedures) will
be stored in a research tissue bank by SIOP for use in future research related to cancer.

Data Collection:

If you agree, data from your medical record will be sent to SIOP. The data will be stored
in secure research databases by SIOP for use in future research related to cancer. One
planned use of the databases is to learn how many patients have choroid plexus tumors, what
type of choroid plexus tumors patients have, and the results of treatment for different
types of choroid plexus tumors.

Other Information:

Before your tissue and/or data is sent to SIOP for storage, your name and any personal
identifying information will be coded to protect your privacy. SIOP will not have access to
the codes that link the data to your identity. Tufts Medical CEnter will not have oversight
of any leftover tissue and/or data that will be stored by SIOP for additional research.

Length of Study:

You will be on-study for as long as you agree to continue having your tissue and/or data
used for research.

This is an investigational study. Up to 190 patients will take part in this study. Up to 6
will be enrolled at M. D. Anderson.

Clinical Research:

The Study Drugs:

The study drugs are all designed to interfere with the growth of cancer cells by blocking
cell division, which may cause the cells to die.

Radiation Therapy:

Participants who are eligible may also receive radiation therapy during the study. The type
of therapy will be "craniospinal" radiation (radiation to the brain and spinal cord) or
"focal" radiation (radiation focused on the tumor only). This will be the doctor's
decision, and the radiation doctor will discuss this treatment option with you if you are
possibly eligible.

Surgery:

Participants who are eligible may also have surgery during the study. This will be if you
have tumor remaining after therapy at certain times in the study, and only if the tumor can
be surgically removed. This will be the doctor's decision, and the study doctor will
discuss this treatment option with you if you are possibly eligible.

Study Groups:

If you are found to be eligible to take part in this study, you will be randomly assigned
(as in the roll of dice) to a study group.

This study is being done in 2 phases. If you are one of the first participants to join the
study, you will be enrolled in Phase I. There are 4 study groups in Phase I, and you will
have an equal chance of being assigned to any of the 4 groups.

If you are one of the later participants to join the study, you will be enrolled in Phase
II. There will be 2 study groups in Phase II, and you will have an equal chance of being
assigned to either group.

- One of the study groups in Phase II will receive the study drugs that are called "Group
1" below. (Although none of the study drugs are FDA-approved, Group 1's study drugs
are considered the standard treatment for choroid plexus tumors.)

- The other study group in Phase II will be the study group from Phase I that had the
best results (Group 2, 3, or 4 as described below).

The study drugs in Cycles 1 and 2 are different in all 4 study groups. All 4 study groups
receive the same study drugs in Cycles 3-6.

Cycles in this study are 28 days long.

Study Drug Administration:

Group 1:

- In Cycle 1, you will receive cyclophosphamide by vein over 2 hours on Days 2 and 3,
etoposide by vein over 1 hour on Days 1-5, and vincristine by vein over 15 minutes on
Day 5.

- In Cycle 2, Group 1 will receive etoposide by vein over 1 hour on Days 1-5, carboplatin
by vein over 2 hours on Days 2 and 3, and vincristine by vein over 15 minutes on Day 5.

Group 2:

In Cycles 1 and 2, Group 2 will receive doxorubicin by vein over 12 hours on Days 1-3,
dactinomycin by vein over 1 hour on Day 1, cisplatin by vein over 6 hours on Day 4, and
vincristine over 15 minutes on Days 8 and 15.

Group 3:

Group 3 will receive methotrexate by vein over 24 hours on Days 1 and 15 of Cycle 1 and Day
1 of Cycle 2.

Group 4:

In Cycles 1 and 2, Group 4 will take temozolomide by mouth once a day on Days 1-5 and
receive irinotecan by vein over 1 hour on Days 1-5.

All Groups:

- In Cycles 3 and 5, you will receive cyclophosphamide by vein over 2 hours on Days 2 and
3, etoposide by vein over 1 hour on Days 1-5, and vincristine by vein over 15 minutes
on Day 5.

- In Cycles 4 and 6, you will receive etoposide by vein over 1 hour on Days 1-5,
carboplatin by vein over 2 hours on Days 2 and 3, and vincristine by vein over 15
minutes on Day 5.

- Depending on your and the doctor's decision, the drugs that you receive by vein may be
given into a central venous catheter. This is a sterile flexible tube that will be
placed into a large vein while you are under local anesthesia. Your doctor will
explain this procedure to you in more detail, and you will sign a separate consent form
for it.

Possible Additional Therapies:

Depending on your age and the disease status, you may receive radiation therapy before Cycle
3. The radiation treatments will be once a day, a few minutes each, 5 days a week for about
6 weeks.

If you have tumor remaining after Cycle 1, after radiation therapy, and/or after your last
study drug dose, you may have surgery if the tumor can be surgically removed. Your doctor
will explain the surgery to you in more detail, and you will sign a separate consent form
for it.

Possible Different Type of Etoposide Administration:

If the tumor is in your cerebrospinal fluid (fluid in your brain and spine) and you have not
received craniospinal radiation, you will receive etoposide "intrathecally" rather than by
vein. This means the drug will be given directly into your cerebrospinal fluid. This will
be done on Days 1 and 28 of every cycle. Your doctor will explain the intrathecal injection
procedure to you in more detail, and you will sign a separate consent form for it.

In this case, etoposide may (depending on your and the doctor's decision) be given into an
Ommaya reservoir or Rickham capsule. These are devices that are surgically placed under the
scalp so that the drug can be given directly into your cerebrospinal fluid. If this applies
to you, the surgeon will explain the surgery to you in more detail, and you will sign a
separate consent form for it.

Drugs to Prevent Side Effects:

On the days you receive cyclophosphamide, you will receive mesna 4 times by vein over 15
minutes (once before, and 3 times after the cyclophosphamide infusion).

On the days you receive etoposide, you may (if needed) receive diphenhydramine by vein over
15 minutes or by mouth.

Group 3 will receive leucovorin by vein over 15 minutes, at 42 hours after the start of the
methotrexate dose, and then every 6 hours until methotrexate is no longer in the body.

If your white blood cell counts become low, you may (if needed) receive filgrastim as an
injection below the skin.

Study Visits:

The study visits will follow a standard schedule for tests and procedures that are done in
connection with chemotherapy. At least once a week, the following tests and procedures will
be performed:

- You will have a physical exam.

- Your medical history will be recorded.

- Blood (about 1-2 teaspoons) will be drawn for routine tests.

If you are in Group 3, you will have blood drawn (about 2 teaspoons each time) for
pharmacokinetic (PK) testing starting 24 hours after every methotrexate dose. This blood
test will be repeated every 6 hours until the doctor decides the methotrexate level has
reached a certain low level. PK testing measures the amount of study drug in the body at
different time points.

Length of Study:

You may receive the study drugs for up to 6 cycles. You will be taken off the study drugs
early if the disease gets worse or intolerable side effects occur.

End-of-Study Visit:

After your last dose of the study drugs:

- Blood (about 2 teaspoons) will be drawn to test your liver and kidney function.

- You will have a hearing test.

- You will have a magnetic resonance imaging (MRI) scan of the brain.

Long-Term Follow-Up:

Once you are off study, you will receive long-term follow-up from then on, according to the
standard of care for brain tumors.

Other Instructions:

Before taking the study drugs, be sure to tell your doctor if:

- you have ever had any unusual or allergic reactions to any of the study drugs

- you have any type of infection (bacterial, viral, or fungal)

- you have any form of heart, kidney, liver, stomach, intestinal, or lung disease

- you have gout

For safety reasons, while you are taking the study drugs:

- Do not take any form of aspirin, ibuprofen, naproxen, or other pain relievers unless
your study doctor approves.

- Do not have any alcohol (beer, wine, or liquor).

- Do not receive any vaccines unless your study doctor approves.

- Avoid contact with people who have recently taken the polio vaccine by mouth.

This is an investigational study. None of the study drugs are FDA-approved to treat choroid
plexus tumors. They are all investigational for this use. Intrathecal etoposide is not FDA
approved or commercially available. At this time, intrathecal etoposide is being used in
research only.

Except intrathecal etoposide, all of the study drugs are FDA-approved and commercially
available for use in other types of cancer:

- Etoposide by vein - for lung cancer

- Carboplatin - for ovarian cancer

- Cisplatin - for testicular cancer

- Vincristine - for leukemia

- Cyclophosphamide - for lymphoma

- Methotrexate - for leukemia

- Doxorubicin - for breast cancer

- Dactinomycin - for kidney cancer (Wilm's tumor)

- Temozolomide - for glioma (a type of brain cancer)

- Irinotecan - for colon cancer

Up to 190 patients will take part in this multicenter study. Up to 6 will be enrolled at
Tufts Medical Center.


Inclusion Criteria:



1. Histological diagnosis of a choroid plexus tumor by a local
pathologist/neuropathologist. This includes choroid plexus papilloma, atypical
choroid plexus papilloma, anaplastic choroid plexus papilloma, malignant choroid
plexus papilloma, and choroid plexus carcinoma.

2. Slides have been sent to the pathology reference center (by declaration of the
sending center).

3. Informed consent signed

4. The first registration on the study was completed or was sent with the same mail or
fax or electronic registration.

5. The reference center has confirmed the receipt of slides sent.

6. The postoperative imaging has been done and the result is available.

7. Disease status and histology: The patient is suffering from either choroid plexus
carcinoma of any stage, OR an atypical choroid plexus papilloma with tumor residual
after maximal possible surgical resection, OR a primary metastatic atypical choroid
plexus papilloma. OR a first recurring choroid plexus papilloma that is either not
resectable or was metastatic, OR a second recurrence of any choroid plexus tumor.

8. The agreement of patient or legal guardian has been documented according to the local
guidelines.

9. For females in reproductive age: pregnancy test negative (both urine or blood test
acceptable)

10. Females in reproductive age, patients must agree to use a medically accepted method
of contraception while receiving protocol-specified medication.

Exclusion Criteria:

1. Previous chemotherapy

2. Previous radiation therapy of the central nervous system

3. White blood cell count < 2000/ uL

4. Platelet count < 85 000 / uL

5. Inadequate kidney function with Creatinine > age adapted upper normal range AND
creatinine clearance or GFR determined by nuclear medicine < 70 ml/min/1.73 m2 Body
surface area

6. Hearing loss more than 30 dB at 3000 Hz or more than 40 dB at 4000 Hz.

7. Echocardiography indicates myocardial dysfunction or weakness

8. Patients who are involuntarily hospitalized because of mental illness

9. Pregnancy

10. ALT or AST elevated higher than three times the upper normal level.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Time to Disease Progression

Outcome Time Frame:

Till disease progression or death (up to 6 cycles of 28-day treatment)

Safety Issue:

Yes

Principal Investigator

Johannes Wolff, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Tufts Medical Center

Authority:

United States: Institutional Review Board

Study ID:

CPT-SIOP-2009

NCT ID:

NCT01014767

Start Date:

November 2009

Completion Date:

November 2017

Related Keywords:

  • Brain Cancer
  • Choroid Plexus Tumors
  • Choroid Plexus Tumors
  • Brain Tumor
  • Chemotherapy
  • Etoposide
  • Carboplatin
  • Vincristine
  • Cyclophosphamide
  • Methotrexate
  • Doxorubicin
  • Cisplatin
  • Dactinomycin
  • temozolomide
  • irinotecan
  • Pediatrics
  • Brain Neoplasms
  • Choroid Plexus Neoplasms

Name

Location

Tufts Medical CenterBoston, Massachusetts  02111
Children's Cancer Hospital at UT MD Anderson Cancer CenterHouston, Texas  77030
Hasboro Children's HospitalProvidence, Rhode Island  02903